Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations
JAMA — Mair MJ, Berger JM, Berghoff AS, et al. | January 24, 2022
Researchers aimed at assessing antibodies development in patients with cancer following SARS-CoV-2 vaccination and comparing their antibody levels with those of healthcare workers.
A total of 901 samples from 595 patients with hematooncological diseases and a control group of health care workers were assessed in this cohort study.
There could be detection of anti–SARS-CoV-2 spike antibodies after full immunization, although lower antibody levels were observed in patients than in health care workers.
However, impaired seroconversion occurs in specific subgroups, such as patients who received B-cell–targeting therapy.
These findings emphasize the necessity for dedicated vaccination trials in patients with cancer.
Read the full article on JAMA